Almac has launched the Xcel array, a biomarker discovery platform that is suitable for the identification of biomarkers within multiple disease areas and for research in cross-disease areas.
The Xcel array contains 92,000 transcripts and the technology is optimised for use with Formalin Fixed Paraffin Embedded (FFPE) tissue.
The new high-density transcriptome-based microarray is based on the industry-standard Affymetrix Genechip platform.
The content of Xcel has been derived from proprietary sequence data, as well as mining public gene expression and sequence databases.
The design methodologies of the array are derived from validated methods developed for Almac's range of cancer disease-specific arrays (DSAs).
The Xcel array is the latest addition to the company's portfolio of proprietary discovery arrays, which includes Breast DSA, Colorectal DSA, Lung Cancer DSA, Ovarian Cancer DSA and Prostate Cancer DSA.
